Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) – Equities research analysts at Jefferies Group issued their FY2022 earnings estimates for shares of Zynerba Pharmaceuticals in a research report issued to clients and investors on Monday. Jefferies Group analyst B. Amin forecasts that the company will earn $0.06 per share for the year.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its quarterly earnings results on Monday, March 12th. The company reported ($0.60) earnings per share for the quarter, hitting the consensus estimate of ($0.60). During the same period last year, the company earned ($0.71) EPS.
ZYNE has been the topic of several other reports. Cantor Fitzgerald began coverage on Zynerba Pharmaceuticals in a research report on Monday, March 5th. They set a “buy” rating and a $17.00 price target on the stock. Zacks Investment Research downgraded Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 18th. HC Wainwright set a $23.00 price target on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday. Ladenburg Thalmann Financial Services assumed coverage on Zynerba Pharmaceuticals in a research report on Monday, January 29th. They set a “buy” rating and a $25.50 price target on the stock. Finally, Oppenheimer restated a “hold” rating on shares of Zynerba Pharmaceuticals in a research report on Tuesday. One analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the stock. Zynerba Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $17.77.
Shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) traded down $0.33 on Wednesday, reaching $10.06. The company’s stock had a trading volume of 397,815 shares, compared to its average volume of 349,024. The firm has a market cap of $142.80, a P/E ratio of -4.07 and a beta of 5.06. Zynerba Pharmaceuticals has a 12 month low of $5.42 and a 12 month high of $25.95.
Several large investors have recently bought and sold shares of the company. Nationwide Fund Advisors acquired a new stake in shares of Zynerba Pharmaceuticals during the 2nd quarter valued at about $110,000. BlackRock Inc. grew its position in shares of Zynerba Pharmaceuticals by 1.1% during the 4th quarter. BlackRock Inc. now owns 678,697 shares of the company’s stock valued at $8,497,000 after acquiring an additional 7,091 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in shares of Zynerba Pharmaceuticals during the 2nd quarter valued at about $158,000. New York State Common Retirement Fund acquired a new stake in shares of Zynerba Pharmaceuticals during the 2nd quarter valued at about $207,000. Finally, Parametric Portfolio Associates LLC purchased a new position in Zynerba Pharmaceuticals in the 2nd quarter valued at about $223,000. Hedge funds and other institutional investors own 29.07% of the company’s stock.
In other Zynerba Pharmaceuticals news, major shareholder Michael Rapp bought 15,000 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were purchased at an average cost of $12.99 per share, for a total transaction of $194,850.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 9.91% of the stock is owned by company insiders.
WARNING: “Jefferies Group Weighs in on Zynerba Pharmaceuticals Inc’s FY2022 Earnings (ZYNE)” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://ledgergazette.com/2018/03/14/jefferies-group-weighs-in-on-zynerba-pharmaceuticals-incs-fy2022-earnings-zyne.html.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.